Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

Iovance Biotherapeutics is supported by accelerating commercial traction for AMTAGVI, with 2Q26 total revenue of $99.3 million, Amtagvi revenue of $91 million, and management raising FY26 total revenue guidance to $410-420 million on sustained U.S. demand and clearer visibility from current manufacturing schedules. The outlook is also strengthened by expanding access and operating leverage, as the authorized treatment center network has grown to about 100 sites and is on track for at least 110 by YE26, while gross margin improved to 56% from 41% in 1Q26 and the company ended 2Q26 with $303.7 million in cash and cash equivalents. Beyond the current product cycle, the company’s differentiated autologous TIL platform, broad intellectual-property and manufacturing moat, and advancing pipeline catalysts across NSCLC, sarcoma, melanoma, and endometrial cancer create multiple paths for durable long-term growth and support the positive fundamental view.

Iovance Biotherapeutics is facing a fundamentally challenging outlook because its valuation is still heavily dependent on clinical and commercial execution of a narrow set of autologous TIL therapies, with AMTAGVI for metastatic melanoma accounting for 47% of the model’s value and lifileucel in endometrial cancer, NSCLC, sarcoma, and 1L advanced melanoma contributing the rest. The business remains exposed to meaningful binary risks, including failed or inconclusive clinical trials and the possibility that it cannot secure adequate funding to advance programs through development, while the cited model itself shows only probability-adjusted 2030E revenues of approximately $1,200.8MM and probability-adjusted 2030 EPS of approximately $0.11. Even though the outlook incorporates commercial traction and larger melanoma sales assumptions, the company still depends on converting a highly specialized, capital-intensive platform into durable revenue across multiple indications, a difficult task that leaves the stock vulnerable if uptake, reimbursement, or trial progress disappoints.